Our accelerated operations model, Accelero maximizes all parts of SCRI to accelerate drug development and optimize clinical trial delivery. Coordinated through our CRO, SCRI Development Innovations, Accelero enhances connectivity to SCRI research sites, which in turn maximizes site contributions, optimizes site activation timelines, and synchronizes end-to-end clinical research management. Learn more.

Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an ora...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patient...

Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

March is Colorectal Cancer Awareness Month. Colorectal cancer is now the number one cause of cancer death in adults under 50, with cases rising 1% annually in this group.

Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological a...

New leaders of the Sarah Cannon Research Institute discuss its mission and priorities amid a changing landscape in community oncology.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Dr. David Spigel is a medical oncologist at SCRI Oncology Partners in Nashville and President and Chief Medical Officer for Sarah Cannon Research Institute.

Please enable JavaScript to proceed.

PurposeThe HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance the...

YouTube video by Sarah Cannon Research Institute

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story

From diagnosis to treatment, here is what patients need to know about stage 1 testicular cancer.

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.